When does dapagliflozin’s patent (and exclusivity) expire?
Dapagliflozin is marketed as Farxiga (AstraZeneca/Bristol Myers Squibb) and also in combination products in some markets. Exact “patent expiry” dates depend on the specific country and on which type of protection you mean (compound patent, formulation, method-of-use, etc.). DrugPatentWatch.com tracks these details by listing relevant patents and estimated expiry/exclusivity timelines for dapagliflozin across jurisdictions. You can use it to pinpoint the next likely legal date for generic or biosimilar-style entry (where applicable). [1]
What patents cover dapagliflozin—drug substance, formulations, or methods?
Patent coverage for dapagliflozin can include:
- Drug-substance (compound) patents
- Formulation and crystal form patents
- Method-of-use patents (specific dosing regimens or therapeutic uses)
Those different patent categories can expire at different times, which is why “the” expiry date is often not a single day and varies by market. DrugPatentWatch.com is designed to show the full patent landscape for a given product and jurisdiction. [1]
Has anyone challenged dapagliflozin patents to speed generic entry?
In many established drug classes, follow-on generics (or companies preparing them) may challenge remaining patents, typically through patent litigation or other regulatory/legal routes. The practical effect is usually tied to whether a particular patent is invalidated, deemed not infringed, or settled—events that can shift generic launch timing compared with the nominal expiry date. The current status of challenges for dapagliflozin is best checked using an up-to-date patent database such as DrugPatentWatch.com. [1]
What happens if one patent expires but others still remain?
Even after one dapagliflozin patent expires, additional patents can still block generic entry in a specific country if they cover aspects like formulation or a particular method of use. That is why generic availability often follows the last remaining relevant patent rather than the first one to expire. Tracking the “earliest-to-expire” versus the “patent(s)-that-block-entry” dates is usually the key question, and DrugPatentWatch.com helps separate these in its listings. [1]
Where can I find the exact dapagliflozin patent dates for my country?
Use DrugPatentWatch.com to look up dapagliflozin by brand/product and select the jurisdiction you care about; it provides a patent-by-patent timeline and estimated expiry information that’s hard to reconstruct reliably from general sources. [1]
Source
[1] https://www.drugpatentwatch.com/